ArticleFrontiers in oncology2026
Ten-year risk of second primary malignancies among chemotherapy-treated early-stage breast cancer survivors: a multicentre cohort study from the Turkish Oncology Group.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: As survivorship improves, second primary malignancies (SPMs) have become a clinically relevant late effect of localised breast cancer treatment. Evidence from the Middle East and Balkans is scarce, and contemporary data from Türkiye are lacking. Materials and methods: We conducted a rigorous retrospective, multicentre cohort study within the Turkish Oncology Group across 14 tertiary centres. The medical records of 6, 552 women with early-stage breast cancer (2008-2022) were meticulously reviewed. SPMs were defined according to IARC/SEER multiple-primary rules, and only the first SPM per patient was included. We calculated standardised incidence ratios (SIRs) with exact Poisson 95% confidence intervals (CIs) using age- and period-specific national female incidence rates averaged over the 2010-2020 period. Person-years were stratified by attained age and calendar period to ensure the accuracy and reliability of our results. Results: During a median follow-up of 5.4 years (interquartile range, 1.1-9.4), 174 women developed pathologically confirmed SPMs. Breast cancer survivors had a significantly higher SPM risk compared to the general population (SIR, 1.66; 95% CI, 1.42-1.93). Excluding breast primaries, the excess remained (SIR 1.78; 95% CI, 1.51-2.09). The most significant increases were observed for thyroid cancer (SIR 7.09; 95% CI, 4.45-10.70) and sarcomas (SIR 7.14; 95% CI, 3.43-13.10), followed by ovarian (SIR 4.35; 95% CI, 2.58-6.89) and pancreatic cancers (SIR 4.08; 95% CI, 1.11-10.50). Risks for colorectal, brain, bladder, kidney, gastric, and contralateral breast cancers did not differ from expectations (all p>0.05). Conclusion: Turkish breast cancer survivors face a markedly increased SPM risk, especially for thyroid, sarcoma, and ovarian cancers. These findings should be interpreted cautiously in the context of treatment selection, surveillance intensity, hereditary predisposition, and regional background cancer risks. Prospective population-based studies incorporating detailed treatment exposures, germline testing, and standardized follow-up data are needed to clarify the mechanisms underlying these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.